Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Long Covid–the disease encompassing the post-acute sequelae of SARS-CoV-2 (PASC)—
affects millions of people around the world. Prevention of PASC is an urgent public health …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk …

Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still
needed, particularly for individuals in whom vaccines are less effective, such as the …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …

We conducted a retrospective cohort study to assess whether treatment with
nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 …

The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …